Open AccessLurasidone‐induced hyperosmolar hyperglycemic syndrome: A case report
Author(s) -
Hanyu Shota,
Kojima Yusuke,
Murai Toshiya,
Kawashima Hirotsugu
Publication year - 2022
Publication title -
neuropsychopharmacology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.661
H-Index - 13
ISSN - 2574-173X
DOI - 10.1002/npr2.12259
Subject(s) - lurasidone , medicine , intensive care medicine , pediatrics , psychiatry , antipsychotic , schizophrenia (object oriented programming)
Abstract Introduction Lurasidone has few metabolic adverse effects and is recommended as an alternative when other antipsychotic drugs considerably increase body weight or blood sugar concentrations. Case presentation An 81‐year‐old man with bipolar disorder developed hyperosmolar hyperglycemic syndrome as a side effect of lurasidone. Routine monitoring of blood glucose concentrations led to the early detection and treatment of this disease, preventing life‐threatening complications. Discussion and conclusion We describe a rare case of lurasidone‐induced hyperosmolar hyperglycemic syndrome. The mortality rate of this syndrome is estimated to be up to 20%. This rate is significantly higher than that of diabetic ketoacidosis (currently <2%). Although lurasidone is considered to have a low risk of raising blood glucose concentrations, symptoms of hyperglycemia must be evaluated and blood glucose concentrations should be monitored regularly.